Fig. 1 · Structure

Cat. No.: A10943
CAS No.: 157283-68-6
Formula: C₂₆H₃₅F₃O₆
Mol. Weight: 500.55

Documents & Downloads

Travoprost

FP Prostaglandin Receptor Agonist

Travoprost is a selective FP prostaglandin receptor agonist characterized by its high affinity for this target. It exhibits significant ocular hypotensive effects, making it a valuable compound in the research of glaucoma and ocular hypertension. Its ability to lower intraocular pressure positions Travoprost as a key reagent for studies focused on the treatment and management of these eye conditions.

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vivo Studies

In naïve rhesus monkeys, a single topical treatment with Travoprost produced a transient, non-significant IOP increase at 2 h and significantly lower IOP than placebo at 23 h. Repeated daily topical Travoprost significantly reduced IOP at 24 h after each treatment, with the effect vanishing at 48 h after the last treatment. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Intraocular pressure after a single topical treatment

Animal study · Eight (four male and four female) naïve rhesus monkeys (M3–M10) [1]

Naïve rhesus monkeys received a single ocular topical treatment with Travoprost, with Eyestream® administered to the contralateral eye. A transient, non-significant IOP increase occurred at 2 h, followed by significantly lower IOP than placebo at 23 h.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
IOP was measured using the TonoVet™ rebound tonometer	IOP −2.4 mmHg	[1]

Conditions shared by the study groups

Route: ocular topically
Treatment course: a single treatment was administered at 10:00 AM (0 h) immediately after a baseline IOP measurement; Post-treatment IOP was assessed at 2 h, 7 h, 23 h, and 47 h

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
Travoprost 1 drop (30 μl); 0.004% travoprost	The contralateral eye received 1 drop (30 μl) of Eyestream®	a transient but not statistically significant (p=0.26) IOP increase (1.1 mmHg) 2 h after treatment; At 23 h, the Travatan®-treated eyes had a significantly (p<0.05) lowered IOP (−2.4 mmHg) compared to the placebo-treated eyes	[1]

Travoprost 1 drop (30 μl); 0.004% travoprost: Model: Eight (four male and four female) naïve rhesus monkeys (M3–M10); Reported limits: Not stated in the sentences used: vehicle.

Methods and source locations

Compound reported in the paper: Travoprost; Compound label in the paper: Travatan

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Rebound tonometer (S9); Methods > Measurement of monkey IOP (S20); Methods > Drug effects on IOP (S27, S28, S29, S30, S31); Results > Effects of Travatan® on monkey IOP (S56, S58)

IOP was measured using the TonoVet™ rebound tonometer: IOP was measured using the TonoVet™ rebound tonometer; comparator: The contralateral eye received 1 drop (30 μl) of Eyestream® — Methods > Rebound tonometer (S9); Results > Effects of Travatan® on monkey IOP (S56, S58)

Travoprost 1 drop (30 μl); 0.004% travoprost · Methods > Drug effects on IOP (S27, S28, S30, S31); Results > Effects of Travatan® on monkey IOP (S56, S58)

Intraocular pressure following repeated daily topical treatment

Animal study · Eight (four male and four female) naïve rhesus monkeys (M3–M10) [1]

Naïve rhesus monkeys received daily topical Travoprost, with Eyestream® as placebo. IOP was significantly reduced at 24 h after each treatment; the effect vanished at 48 h after the last treatment.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
IOPs were measured at 0 h (immediately before the 0 h dosing), 24 h (immediately before the 24 h dosing), 48 h (immediately before the 48 h dosing), 72 h, and 96 h	IOP −2.0 mmHg to −2.2 mmHg	[1]

Conditions shared by the study groups

Route: topically
Treatment course: administered daily at 10:00 AM for three consecutive days (0 h, 24 h, and 48 h)

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
Travoprost 1 drop (30 μl); 0.004% travoprost	Eyestream® (placebo)	a significant (p<0.05 or p<0.01) reduction in IOP (ranging from −2.0 mmHg to −2.2 mmHg) 24 h after each treatment; The drug effect vanished 48 h after the last drug treatment	[1]

Travoprost 1 drop (30 μl); 0.004% travoprost: Model: Eight (four male and four female) naïve rhesus monkeys (M3–M10); Reported limits: Not stated in the sentences used: vehicle.

Methods and source locations

Compound reported in the paper: Travoprost; Compound label in the paper: Travatan

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Measurement of monkey IOP (S20); Methods > Drug effects on IOP (S28, S32); Results > Effects of Travatan® on monkey IOP (S61, S62); Figure 6 legend (S89)

IOPs were measured at 0 h (immediately before the 0 h dosing), 24 h (immediately before the 24 h dosing), 48 h (immediately before the 48 h dosing), 72 h, and 96 h: IOPs were measured at 0 h (immediately before the 0 h dosing), 24 h (immediately before the 24 h dosing), 48 h (immediately before the 48 h dosing), 72 h, and 96 h; comparator: Eyestream® (placebo) — Methods > Drug effects on IOP (S32); Results > Effects of Travatan® on monkey IOP (S61, S62)

Travoprost 1 drop (30 μl); 0.004% travoprost · Methods > Drug effects on IOP (S28, S32); Results > Effects of Travatan® on monkey IOP (S61, S62); Figure 6 legend (S89)

Specifications

Manufacturer	Adooq Bioscience
Actions	Agonist
CAS Number	157283-68-6
Applications	FP Prostaglandin Receptor Agonist
Formula	C₂₆H₃₅F₃O₆
Molecular Weight	500.55
Synonyms	Fluprostenol isopropyl ester; AL6221; Flu-Ipr
SMILES	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COC2=CC=CC(C(F)(F)F)=C2)[C@H](O)C[C@@H]1O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

[1] Yu W, Cao G, Qiu J, et al. Evaluation of monkey intraocular pressure by rebound tonometer. Mol Vis (2009). PMID: 19898690 Source material

Documents & Downloads

Travoprost

Select a Size

Package Sizes

Travoprost 1 mg

Free Aliquoting for Your Order

In Vivo Studies

Intraocular pressure after a single topical treatment

Conditions shared by the study groups

Intraocular pressure following repeated daily topical treatment

Conditions shared by the study groups

Specifications

Storage & Solubility

In Vitro Solubility

Reported Solubility

Preparing Stock Solutions

Storage

Research References

Added to your cart